Effective maintenance treatment with lenalidomide for a patient with aggressive adult T cell leukemia after chemotherapy

Publication date: Available online 13 April 2019Source: Leukemia Research ReportsAuthor(s): Satoko Oka, Kazuo Ono, Masaharu NohgawaAbstractAdult T cell leukemia/lymphoma (ATL) is incurable with conventional chemotherapies, and allogeneic stem cell transplantation (SCT) is the only curative treatment. Direct antitumor effects and antitumor immune responses are important factors that need to be considered in the treatment of ATL. A phase II study reported long overall survival despite short progression-free survival in patients, implying that lenalidomide confers a survival benefit through immunomodulation for patients with ATL. We herein report that low-dose lenalidomide as maintenance therapy maintained a complete remission in a patient with aggressive ATL, whose condition has since remained stable with no recurrence for 24 months.
Source: Leukemia Research Reports - Category: Hematology Source Type: research